CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

This study tests a combination of chemotherapy (capecitabine + oxaliplatin, known as CapeOX), bevacizumab (a drug that blocks tumor blood vessel growth), and an anti-PD-1 immunotherapy drug as treatment before surgery for people with locally recurrent colorectal cancer — cancer that has come back in the same area after previous surgery. **You may be eligible if:** - Your colorectal cancer has come back locally (not spread to distant organs) after a previous surgery that removed the original tumor (R0 resection) - Your recurrence has been confirmed by imaging and/or biopsy - You have not yet received any treatment for the recurrence (no chemo, radiation, or immunotherapy) - Your first cancer was treated with standard adjuvant chemotherapy after surgery **You may NOT be eligible if:** - Your cancer has spread to distant organs (metastatic) - You have already received treatment for the recurrence - You have serious heart, kidney, or liver problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.